The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - High Enroll
Consulting or Advisory Role - Caris Life Sciences; Exicure; Merck
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Caris Life Sciences
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Regeneron; Replimune
 
Joseph J Sacco
Honoraria - Immunocore
Consulting or Advisory Role - BMS; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Judith Michels
Consulting or Advisory Role - Brenus Pharma; GlaxoSmithKline; Regeneron Pharmaceuticals, Inc.;
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck
 
Tawnya Lynn Bowles
Research Funding - Amgen (Inst); Genentech (Inst); MAVIS (Inst); Natera (Inst); Replimune (Inst)
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Katy K. Tsai
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Inflax; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Other Relationship - Avantis Medical Systems; BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre
Consulting or Advisory Role - Pierre Fabre
Research Funding - BMS, Pfizer, Amgen, GSK, Roche, Novartis, Pierre Fabre, Replimune, MSD, Janssen, Kartos, IFX, Huyabio, Regeneron, IO Biotech, Philogen, Sotio, Kinnate, Astra Zenecca, Cytovation (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Eva Muñoz Couselo
Honoraria - BMS; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; MSD; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Mark R. Middleton
Consulting or Advisory Role - Alkermes; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GRAIL (Inst); Immunocore
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Infinitopes (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Salvarx (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare
 
Adel Samson
Research Funding - Stratosvir; Transgene (Inst); Transgene (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Georgia Beasley
Honoraria - National Comprehensive Cancer Network
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Delcath Systems (Inst); Istari Oncology (Inst); Oncosec (Inst); Replimune (Inst); Skyline Diagnostics (Inst)
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Delcath Systems; Instil Bio; Novartis; Regeneron; Replimune; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Macrogenics (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - Instil Bio
 
Trisha M. Wise-Draper
No Relationships to Disclose
 
Junhong Zhu
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Marcus Viana
Employment - Replimune
Stock and Other Ownership Interests - Replimune
Patents, Royalties, Other Intellectual Property - Zentalis
Travel, Accommodations, Expenses - Replimune
Other Relationship - Replimune
 
Mohammed M. Milhem
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)